Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Jan 15, 2026 · Filed Jan 16, 2026
Gilead Sciences's Chief Commercial Officer sold $373K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$372,930
Shares × reported transaction price
77 days after results of Oct 30, 2025, 26 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $121.26 on Jan 15, 2026, 32% above its 52-week low and 5% below its high, after a 2% drop over the previous 30 trading days
52-week range $91.65 (Jan 16, 2025) to $128.07 (Nov 19, 2025), 81% of the way up, from 251 adjusted closes. 30 trading days earlier: $123.91 on Dec 2, 2025. Describes the past only, not a forecast
A WARN layoff notice covering 34 workers was filed in California on January 21, 2026.
From the official state WARN list, 6 days after the trade. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +13.6% | +2.6% | +10.9% |
| 30 days | +21.7% | +1.0% | +20.7% |
| 90 days | +9.4% | +4.6% | +4.8% |
| 180 days | +7.3% | +9.5% | -2.2% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$17.3M of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.